Toxicological Review of Perfluorodecanoic Acid (Pfda) (Interagency Science Consultation Draft, 2022)

IRIS

Perfluorodecanoic Acid (PFDA)

CASRN 335-76-2 | DTXSID3031860

IRIS Executive Summary (PDF) (7 pp, 393.6 KB)

On this page:

Overview
Background
Downloads

Notice - This site contains archived material(s)

Archive disclaimer
Archived files are provided for reference purposes only. The file was current when produced, but is no longer maintained and may now be outdated. Persons with disabilities having difficulty accessing archived files may contact the Risk Webmaster for assistance. Please use the contact us form if you need additional support.

Overview

In April 2023, the draft Toxicological Review of Perfluorodecanoic Acid (PFDA) and Related Salts and the draft charge to external peer reviewers were released for a 60-day public review and comment period. The Toxicological Review and charge were reviewed internally by EPA and by other federal agencies and White House Offices before public release. Consistent with the May 2009 IRIS assessment development process, all written comments on IRIS assessments submitted by other federal agencies and White House Offices are made publicly available. Accordingly, interagency comments are posted on this site.

Citation

U.S. EPA. Toxicological Review of Perfluorodecanoic Acid (Pfda) (Interagency Science Consultation Draft, 2022). U.S. Environmental Protection Agency, Washington, DC, EPA/635/R-22/004a, 2022.

Top of Page

Background

Perfluorodecanoic Acid (PFDA, CASRN 375-22 -4) is a member of the group per and polyfluoroalkyl substances (PFAS). Concerns about PFDA and other PFAS stem from the resistance of these compounds to hydrolysis, photolysis, and biodegradation, which leads to their persistence in the environment. PFASs are not naturally occurring in the environment; they are man-made compounds that have been used widely over the past several decades in consumer products and industrial applications because of their resistance to heat, oil, stains, grease, and water. PFDA is a breakdown product of other PFASs that are used in stain-resistant fabrics, paper food packaging, and carpets; it was also used for manufacturing photographic film, and it is used as a substitute for longer chain perfluorocarboxylic acids (PFCAs) in consumer products. PFDA has been found to accumulate in agricultural crops and it has been detected in household dust, soils, food products, and surface, ground, and drinking water. As such, exposure is possible via inhalation of indoor or outdoor air, ingestion of drinking water and food, and dermal contact with PFDA-containing products.

History/Chronology

Date	Description
01- Nov 2019	EPA released the Systematic Review Protocol for the PFAS IRIS Assessment (Preliminary Assessment Materials). [Federal Register Notice Nov 8, 2019]
02- Jul 2020	EPA released an update to the Systematic Review Protocol for the PFBA, PFHxA, PFHxS, PFNA, and PFDA IRIS Assessments in response to public comments.
03- Mar 2022	EPA sent an interagency science consultation PFDA draft for review and comment.
04- Apr 2023	EPA released the draft IRIS Toxicological Review of Perfluorodecanoic Acid (PFDA) and Related Salts for a 60-day public comment period and external peer review. EPA also released the interagency science consultation comments from reviewers. [Federal Register Notice: April 10, 2023 ]

Status

The Perfluorodecanoic Acid (PFDA) and Related Salts IRIS assessment was released for public comment in April 2023. Following the public comment period, there will be an external peer review. The assessment will then be revised taking into consideration public and peer review comments.

Top of Page

Download(s)

This download(s) is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy.

1. ATSDR PFDA IASC Comments March 2022 (PDF) (7 pp, 231.4 KB, about PDF)
2. DoD PFDA IASC Comments Mar 2022 (PDF) (6 pp, 96.7 KB, about PDF)
3. EOP OMB PFDA IASC Comments Mar 2022 (PDF) (4 pp, 161.1 KB, about PDF)
4. NIEHS PFDA IASC Comments Mar 2022 (PDF) (8 pp, 258.8 KB, about PDF)
5. NIOSH PFDA IASC Comments Mar 2022 (PDF) (3 pp, 155.3 KB, about PDF)

If you have a disability and the format of any material on our web pages interferes with your ability to access the information, please reach out to us using the Contact Us about IRIS form for assistance. To enable us to respond in a manner most helpful to you, please indicate the nature of the accessibility problem, the web address of the requested material, your preferred format in which you want to receive the material (electronic format (ASCII, etc.), standard print, large print, etc.), and your contact information.